MedMira Board of Directors Update

About this update from Medmira Inc.

[{"type":"text","content":"\n\n\n\nHALIFAX, July 30 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,\nNASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today\nan updated listing of the Company's Board of Directors. The MedMira Board of\nDirectors is comprised of the following individuals:\n\n\nStephen Sham, Chairman of the Board\n\n\nHermes Chan, Director, President & CEO, MedMira Inc.\n\n\nDavid Harris, Director\n\n\nDr. Michael Katz, Director\n\n\nDr. James Smith, Director, VP of Corporate Affairs, MedMira Inc.\n\n\nDr. Shou-Ching Tang, Director\n\n\nFull profiles on each of the Company's directors can be found on\nMedMira's website at www.medmira.com.\n\n\nAbout MedMira\n\n\nMedMira is a leading developer, manufacturer, and marketer of advanced\nrapid diagnostics. Built on the Company's patented rapid flow-through\ntechnology platform, MedMira's single and multiple rapid tests provide\nhospitals, labs, clinics and individuals around the world with reliable,\ndiagnosis for diseases such as HIV and hepatitis C in just three minutes. The\ncompany's tests, which are sold under the Reveal(R), MiraWell(R), MiraCare(TM)\nand Multiplo(TM) brands in global markets, have achieved regulatory approvals\nin Canada, the United States, China, Russia, India, and the European Union.\nMedMira is an approved supplier to US Agency for International Development\n(USAID) and the Pan American Health Organization (PAHO).\n\n\nIn 2006, MedMira launched the Maple Biosciences division to develop and\ncommercialize diagnostic instruments based on biosensor technology platforms.\nFor more information visit www.maplebio.com.\n\n\nMedMira's corporate offices, R&D, and manufacturing facilities are\nlocated in Halifax, Nova Scotia, Canada. For more information visit MedMira's\nwebsite at www.medmira.com.\n\n\nThis news release contains forward-looking statements, which involve risk\nand uncertainties and reflect the company's current expectation regarding\nfuture events. Actual events could materially differ from those projected\nherein and depend on a number of factors including, but not limited to,\nchanging market conditions, successful and timely completion of clinical\nstudies, uncertainties related to the regulatory approval process,\nestablishment of corporate alliances and other risks detailed from time to\ntime in the company quart...

More updates from Medmira Inc.